Sun Bio Inc

Sun Bio Inc has a market capitalization of KRW 96.35 billion and a price-to-earnings ratio of 34.49, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio of 3.34 suggests that the market values the company at a premium to its book value. The enterprise value to EBITDA ratio of 24.77 indicates that the company is trading at a multiple that is higher than the typical range for the pharmaceutical industry. The company's liquidity position is characterized by a current ratio of 0.53, which is below 1, suggesting that the company may have difficulty meeting its short-term obligations with its current assets. Sun Bio Inc's profitability is reflected in a return on equity of 9.68% and a return on assets of 4.6%, which are metrics that are typically used to assess the efficiency of a pharmaceutical company's use of equity and assets. The company's operating margin, calculated as operating income of KRW 5.04 billion on revenue of KRW 13.67 billion, is 36.9%, which is a strong indicator of the company's ability to generate profit from its operations. The gross margin of 60.9% indicates that the company is able to maintain a significant portion of its revenue after accounting for the cost of goods sold. The company's revenue is derived from the production and sale of PEG derivative materials, neutropenia treatments, dry mouth treatments, bio-new drugs, and medical devices. The company's geographic exposure is primarily in domestic and overseas markets, but the specific revenue concentration by region is not disclosed. The company's business is not segmented into distinct geographic regions in the provided data, which limits the ability to assess the risk associated with geographic concentration. Sun Bio Inc's growth trajectory is not explicitly detailed in the provided data, but the company's capital expenditure of KRW -3.24 billion suggests that the company is not currently investing in new projects or expanding its operations. The company's free cash flow of KRW 1.35 billion indicates that it has some flexibility to fund operations or return value to shareholders. The company's operating cash flow of KRW 3.82 billion is positive, which is a positive sign for its ability to generate cash from its core operations. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt suggests that the company's cash reserves are insufficient to cover its long-term debt obligations. The company's debt-to-equity ratio of 0.98 indicates that it is financed by a relatively balanced mix of debt and equity. The company's dilution risk is low, which suggests that there is a minimal threat to shareholder value from new share issuances. Recent events related to Sun Bio Inc are not detailed in the provided data, but the company's financial snapshot and valuation metrics suggest that it is a mid-sized pharmaceutical company with a strong balance sheet and a moderate level of debt. The company's financial performance and risk profile indicate that it is a stable player in the pharmaceutical industry, but the lack of detailed information on recent events limits the ability to assess its current strategic direction.